Meeting
2018 ASCO Annual Meeting
Long-term androgen deprivation, with or without radiotherapy, in locally-advanced prostate cancer: Updated results from a phase III randomized trial.
Authors
Paul Sargos
Institut Bergonié, Bordeaux, France
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer–Local-Regional Disease
Clinical Trial Registration Number
NCT01122121
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5080)
DOI
10.1200/JCO.2018.36.15_suppl.5080
Abstract #
5080
Poster Bd #
307
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
Phase III trial comparing long-term versus short-term androgen deprivation combined with high-dose radiotherapy for localized prostate cancer: GICOR protocol DART01/05.
First Author: A. Zapatero
Poster
2024 ASCO Genitourinary Cancers Symposium
Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).
First Author: Tamim Niazi
Poster
2022 ASCO Annual Meeting
Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.
First Author: Primo "Lucky" N. Lara Jr.
Poster
2020 ASCO Virtual Scientific Program
Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
First Author: Eric Jay Small